🟢 Chimeric Therapeutics is trading 25% up with no clear catalyst identified

Chimeric Therapeutics is trading at A$0.01, up 25%, with no clear catalyst identified for the September 28 move.

• The latest located filing concerned quotation of 22,222,222 shares issued September 22; available coverage does not connect it to the gain.
• An August update reported CHM-2101 Phase 1 trial enrollment ceased after dose-limiting toxicities; it does not explain the rise.
• Available evidence points to an unclear catalyst, with no confirmed company-specific or broader-market driver.